Arthur M.
- Country
- The Netherlands
- Department
- Pulmonology
Research Overview
- A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Non-Inferiority Study of Reduced Dose Pembrolizumab Versus Standard Dose in Advanced Non-Small Cell Lung Carcinoma for Overall Survival Evaluation
- Phase 3 Randomized Study of Zimberelimab and Domvanalimab with Chemotherapy vs. Pembrolizumab with Chemotherapy in Metastatic NSCLC without EGFR/ALK Aberrations
Data & Insights
Has run more than one trial at 69 of 165 partner sites.
Specializations
Lung Cancer Immunotherapy
The investigator specializes in innovative immunotherapy approaches for non-small cell lung cancer (NSCLC), with particular emphasis on advanced and metastatic disease states.
- PD-L1 targeted therapies
- Anti-TIGIT antibody combinations
- Novel immunotherapy combinations
Research activities focus on evaluating treatment efficacy through survival outcomes in NSCLC patients.
Treatment Optimization
Expertise in developing and assessing optimized treatment protocols for lung cancer patients, particularly in the context of first-line therapies.
- Dose optimization studies
- Combination therapy assessment
- Treatment cost-effectiveness
Investigation of innovative dosing strategies to enhance treatment efficacy and sustainability.
Precision Medicine
Focus on personalized treatment approaches for lung cancer patients, incorporating biomarker-driven patient selection and targeted therapeutic strategies.
- PD-L1 expression analysis
- Biomarker-guided therapy
- Treatment response assessment
Specialized research in patient stratification for optimal therapeutic outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.